PE20160877A1 - Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion - Google Patents

Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion

Info

Publication number
PE20160877A1
PE20160877A1 PE2016000398A PE2016000398A PE20160877A1 PE 20160877 A1 PE20160877 A1 PE 20160877A1 PE 2016000398 A PE2016000398 A PE 2016000398A PE 2016000398 A PE2016000398 A PE 2016000398A PE 20160877 A1 PE20160877 A1 PE 20160877A1
Authority
PE
Peru
Prior art keywords
amino acids
sequence
heterogenic
populations
recombinant human
Prior art date
Application number
PE2016000398A
Other languages
English (en)
Spanish (es)
Inventor
Michael Anthony Jankowski
Keith Johnson
Wendy Carol Piacenza
Stacey B Weston
Michael Shamashkin
Penelope Jane Sharpe
Mary Beth Switzer
Jason C Rouse
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20160877A1 publication Critical patent/PE20160877A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
PE2016000398A 2013-09-24 2014-09-16 Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion PE20160877A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24

Publications (1)

Publication Number Publication Date
PE20160877A1 true PE20160877A1 (es) 2016-09-11

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000398A PE20160877A1 (es) 2013-09-24 2014-09-16 Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion

Country Status (19)

Country Link
US (3) US9757434B2 (cg-RX-API-DMAC7.html)
EP (1) EP3049434A1 (cg-RX-API-DMAC7.html)
JP (1) JP6429885B2 (cg-RX-API-DMAC7.html)
KR (1) KR101988705B1 (cg-RX-API-DMAC7.html)
CN (2) CN105579468A (cg-RX-API-DMAC7.html)
AR (1) AR097732A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014326257B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016005899A8 (cg-RX-API-DMAC7.html)
CA (1) CA2924981C (cg-RX-API-DMAC7.html)
HK (1) HK1218760A1 (cg-RX-API-DMAC7.html)
IL (2) IL244258A0 (cg-RX-API-DMAC7.html)
MX (1) MX373466B (cg-RX-API-DMAC7.html)
MY (1) MY173548A (cg-RX-API-DMAC7.html)
PE (1) PE20160877A1 (cg-RX-API-DMAC7.html)
RU (1) RU2648144C2 (cg-RX-API-DMAC7.html)
SA (1) SA516370751B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201601221XA (cg-RX-API-DMAC7.html)
TW (1) TWI631134B (cg-RX-API-DMAC7.html)
WO (1) WO2015044836A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
PE20190661A1 (es) * 2016-06-17 2019-05-08 Portola Pharm Inc Preparacion de derivados del factor xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
JP2008509688A (ja) * 2004-08-17 2008-04-03 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 改変ビタミンｋ依存性ポリペプチド
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
DK2915564T3 (da) * 2007-09-28 2021-02-08 Alexion Pharma Inc Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
AU2009264282B2 (en) 2008-06-24 2013-04-18 Octapharma Ag A process of purifying coagulation factor VIII
JP5709316B2 (ja) 2008-11-14 2015-04-30 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法
US8436144B2 (en) 2008-12-19 2013-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
EP2453910B1 (en) * 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
EA201291482A1 (ru) * 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
AU2012315516B2 (en) 2011-09-30 2017-05-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
CA2928762A1 (en) 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
MX375355B (es) 2014-01-24 2025-03-04 Pfizer Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral.

Also Published As

Publication number Publication date
BR112016005899A8 (pt) 2018-02-06
KR20160044034A (ko) 2016-04-22
CN105579468A (zh) 2016-05-11
US20150182604A1 (en) 2015-07-02
TWI631134B (zh) 2018-08-01
AU2014326257A1 (en) 2016-03-10
IL244258A0 (en) 2016-04-21
BR112016005899A2 (pt) 2017-09-26
TW201524996A (zh) 2015-07-01
JP6429885B2 (ja) 2018-11-28
AU2014326257B2 (en) 2017-08-10
KR101988705B1 (ko) 2019-06-12
EP3049434A1 (en) 2016-08-03
CA2924981A1 (en) 2015-04-02
WO2015044836A1 (en) 2015-04-02
US20170333535A1 (en) 2017-11-23
MX2016003871A (es) 2016-08-04
RU2648144C2 (ru) 2018-03-22
IL279396A (en) 2021-01-31
MX373466B (es) 2020-05-25
CA2924981C (en) 2020-03-31
MY173548A (en) 2020-02-04
RU2016108608A (ru) 2017-10-26
CN112195169A (zh) 2021-01-08
SG11201601221XA (en) 2016-04-28
US20210106658A1 (en) 2021-04-15
AR097732A1 (es) 2016-04-13
HK1218760A1 (zh) 2017-03-10
JP2016535071A (ja) 2016-11-10
US9757434B2 (en) 2017-09-12
US10660946B2 (en) 2020-05-26
SA516370751B1 (ar) 2018-04-05

Similar Documents

Publication Publication Date Title
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
PE20140982A1 (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
CO7051009A2 (es) Composiciones del factor viii y métodos para hacerlas y usarlas
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
PE20180128A1 (es) Compuestos antisenescentes y usos de los mismos
EA201591839A1 (ru) Терапевтические пептиды
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
GT201700224A (es) Proteína de unión a rgma y su uso
PE20200894A1 (es) Polipeptidos variantes del factor de crecimiento tipo insulina 1
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
BR112017014580A8 (pt) Método para obter um isolado peptídico a partir de uma biomassa de microalgas enriquecidas com proteína
PE20160877A1 (es) Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion
AR094835A1 (es) Péptidos bioactivos cortos que promueven la cicatrización de las heridas
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
AR092736A1 (es) Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r
PL3648788T3 (pl) Leczenie krwawienia z przewodu pokarmowego u pacjentów z ciężką chorobą von willebranda poprzez podanie rekombinowanego vwf
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa